DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Newsmart
  • NewsPlus
  • Private Markets
  • Risk & Compliance
  • WSJ.com
  • WSJ Pro
  • WSJ Conference
  • WSJ Video
NEWS CORP
  • Big Decisions
  • Business Spectator
  • Checkout51
  • Harper Collins
  • New York Post
  • PropTiger
  • REA
  • realtor.com
  • Storyful
  • The Australian
  • The Sun
  • The Times
ダウ平均 ▲
18867.93 -0.19%
  S&P 500 ▲
2181.90 -0.24%
  ナスダック ▲
5321.51 -0.23%
  米10年債 ▲
0/32 yield 2.357%
  原油 ▲
45.58 0.35%
  ユーロ/ドル ▲
1.0591 -0.34%
 
Subscribe Now Sign In
The Wall Street Journal
日本 (Japan)
  • U.S.
  • Asia
  • Europe
  • India
  • América Latina
  • Brasil
  • 中国 (China)
  • 日本 (Japan)
2016年11月20日
Sections
My Journal
  • ホーム
  • 経済
  • マーケット
  • ビジネス
  • テクノロジー
  • 国際
  • 国内
  • オピニオン・社説
  • ライフ
  • バロンズ
  • SHOW ALL SECTIONS HIDE ALL SECTIONS
    • 経済
      • 金融政策ウォッチ
      • Heard on the Street
    • マーケット
      • マーケットデータ
    • テクノロジー
      • ガジェットレビュー
    • 国際
      • 北米
      • 米大統領選特集
      • アジア・オセアニア
      • 欧州
      • 中東・アフリカ
      • China's World
      • China Real Time Report
    • 国内
      • 編集長インタビュー
    • オピニオン・社説
      • オピニオ ン
      • 社説
    • ライフ
      • キャリア
      • ヘルス
    HIDE ALL SECTIONS
Sign In
  • ホーム
  • 経済
    • 金融政策ウォッチ
    • Heard on the Street
  • マーケット
    • マーケットデータ
  • ビジネス
  • テクノロジー
    • ガジェットレビュー
  • 国際
    • 北米
    • 米大統領選特集
    • アジア・オセアニア
    • 欧州
    • 中東・アフリカ
    • China's World
    • China Real Time Report
  • 国内
    • 編集長インタビュー
  • オピニオン・社説
    • オピニオ ン
    • 社説
  • ライフ
    • キャリア
    • ヘルス
  • バロンズ
Search
Subscribe Sign In

Pfizer Inc. PFE (U.S.: NYSE)

View All companies
  • AT CLOSE 4:00 PM EST 11/18/16
  • $31.48 USD
  • -0.25 -0.79%
  • Volume 22,760,381
  • AFTER HOURS 6:31 PM EST 11/18/16
  • $31.48 0.00 0.00%
  • AFTER HOURS Vol 1,396,046
  • Volume 22,760,381
  • 65 Day Avg Vol 23,858,402
  • 1 Day Range 31.44 - 31.95
  • 52 Week Range 28.25 - 37.39 (02/08/16 - 08/01/16)
  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • YTD
  • 1 Y
  • 3 Y
  • $
  • %
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 31.95
  • Prior Close 31.73 (11/17/16)
  • 1 Day
  • PFE -0.79%
  • DJIA -0.19%
  • S&P 500 -0.24%
  • Health Care/Life Sciences -1.03%
  • Overview

News Pfizer Inc.PFE

    • 11/18/16
    • Press Release
    Pfizer Announces Pricing of Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019
    • Press Release
    • 11/17/16
    • Press Release
    Pfizer Files 8K - Other Events >PFE
    • Press Release
    • 11/16/16
    • Press Release
    PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer's IBRANCE(R) (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer
    • Press Release
    • 11/15/16
    • Press Release
    Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ(R) (Tofacitinib Citrate) for Psoriatic Arthritis
    • Press Release
    • 11/14/16
    • Press Release
    Pfizer Prices $6,000,000,000 Debt Offering
    • Press Release
    • 11/14/16
    • Dow Jones Newswires
    Correction to Celebrex Article on Sunday
    • Dow Jones Newswires
    • 11/14/16
    • Press Release
    CORRECTING and REPLACING: Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019
    • Press Release
    • 11/14/16
    • MarketWatch.com
    5 big hurdles to repealing Obamacare
    • MarketWatch.com
    • 11/14/16
    • Press Release
    Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019
    • Press Release
    • 11/14/16
    • Press Release
    Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers
    • Press Release
    • 11/14/16
    • Dow Jones Newswires
    Study Suggests Celebrex Isn't Riskier Than Rival Pain Drugs
    • Dow Jones Newswires
    • 11/14/16
    • The Wall Street Journal
    Study Suggests Celebrex Isn’t Riskier Than Rival Pain Drugs
    • The Wall Street Journal
    • 11/13/16
    • Press Release
    Landmark Study Demonstrates Pfizer's Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen
    • Press Release
    • 11/13/16
    • Dow Jones Newswires
    Study Suggests Celebrex Isn't Riskier Than Rival Pain Drugs
    • Dow Jones Newswires
    • 11/11/16
    • Press Release
    Pfizer Announces Major Expansion of Humanitarian Assistance Program
    • Press Release
    • 11/10/16
    • Press Release
    First Majestic Silver trade offers a 2.42% return in 71 days, or find similar option trades on SPDR Gold Trust, Ralph Lauren, Pfizer Inc., and Magellan Health Inc.
    • Press Release
    • 11/10/16
    • Press Release
    Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis(R) (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016
    • Press Release
    • 11/10/16
    • Press Release
    IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
    • Press Release
    • 11/07/16
    • Press Release
    Pfizer to Present Additional Research For XELJANZ(R) (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis
    • Press Release
    • 11/06/16
    • MarketWatch.com
    Drug companies spend $109 million to block vote to lower drug prices
    • MarketWatch.com
    • 11/05/16
    • Barron's
    Samsung BioLogics IPO: Too Expensive
    • Barron's
    • 11/03/16
    • Press Release
    Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity
    • Press Release
    • 11/02/16
    • Press Release
    Pfizer's Prevenar 13(R) Receives Approval For Use in Infants and Children in China
    • Press Release
    • 11/01/16
    • Dow Jones Newswires
    Pfizer Cuts Outlook, Ends Development of Cholesterol Drug -- 2nd Update
    • Dow Jones Newswires
    • 11/01/16
    • The Wall Street Journal
    Pfizer Cuts Outlook, Ends Development of Cholesterol Drug
    • The Wall Street Journal
    • 11/01/16
    • The Wall Street Journal
    Big Pharma Sales Need a Booster Shot​
    • The Wall Street Journal
    • 11/01/16
    • Dow Jones Newswires
    Shire Cuts Guidance After Posting Third-Quarter Loss--Update
    • Dow Jones Newswires
    • 11/01/16
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 11/01/16
    • WSJ Blogs
    Margin Debt Is on the Rise Again
    • WSJ Blogs
    • 11/01/16
    • Dow Jones Newswires
    Pfizer Cuts Outlook, Ends Development of Cholesterol Drug
    • Dow Jones Newswires
    • 11/01/16
    • Press Release
    PFIZER REPORTS THIRD-QUARTER 2016 RESULTS
    • Press Release
    • 11/01/16
    • Press Release
    Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
    • Press Release
    • 10/31/16
    • Press Release
    Learn how to target a 17% return on Cardinal Health, or get option-trade ideas on Capital One, Dean Foods, Pfizer Inc. and Regeneron Pharmaceuticals or any stock you choose
    • Press Release
    • 10/31/16
    • Press Release
    (PR) European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
    • Press Release
    • 10/29/16
    • Barron's
    These Top Stockpickers Have Stumbled
    • Barron's
    • 10/24/16
    • WSJ Blogs
    What Presidential Election? Deal Making Has Biggest Week Since 1999
    • WSJ Blogs
    • 10/18/16
    • Dow Jones Newswires
    J&J Brushes off Looming Biosimilar Competition -- 2nd Update
    • Dow Jones Newswires
    • 10/18/16
    • The Wall Street Journal
    J&J Brushes Off Looming Biosimilar Competition
    • The Wall Street Journal
    • 10/17/16
    • Dow Jones Newswires
    Pfizer Plans to Launch Remicade Biosimilar in November -- Update
    • Dow Jones Newswires
    • 10/17/16
    • The Wall Street Journal
    Pfizer Plans to Launch Remicade Biosimilar in November
    • The Wall Street Journal
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    31.32 (11/18/16)
  • EPS (TTM)
    $1.00
  • Market Cap
    $191.03 B
  • Shares Outstanding
    6.07 B
  • Public Float
    6.06 B
  • Yield
    3.81% (11/18/16)
  • Latest Dividend
    $0.30 (12/01/16)
  • Ex-Dividend Date
    11/08/16
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (10/31/16)

  • Shares Sold Short
    47.03 M
  • Change from Last
    1.04%
  • Percent of Float
    0.78%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    0.92
    Net Money Flow ($)
    -13.67 M

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors PFE

Company Change P/E (TTM)
AMGN

Amgen Inc.

-1.45% -2.13 14.49
AZN

AstraZeneca PLC ADR

-0.84% -0.23 29.39
GSK

GlaxoSmithKline PLC ADR

-0.88% -0.34 313.15
NVS

Novartis AG ADR

-2.62% -1.90 25.09
ABT

Abbott Laboratories

-1.36% -0.55 44.00
BMY

Bristol-Myers Squibb Co.

+0.14% +0.08 27.82
JNJ

Johnson & Johnson

-0.35% -0.41 20.42
LLY

Eli Lilly & Co.

-1.34% -1.04 33.59
MRK

Merck & Co. Inc.

-1.32% -0.83 31.57
MYL

Mylan N.V.

-2.90% -1.09 71.51
  • More information on PFE
  • Competitor Data Provided By: capital cube

Profile PFE

Pfizer, Inc. is a research-based, global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines. It operates through the following segments: Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare,...

235 East 42nd Street
New York New York 10017
United States

  • Email
  • Website
  • Map
  • Employees 97,900
    Sector Pharmaceuticals
  • Sales or Revenue 48.85 B
    Industry Health Care/Life Sciences
  • 1Y Sales Change -1.52%
    Fiscal Year Ends December 31 Download Reports
  • Ian C. Read Chairman & Chief Executive Officer
  • Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
  • Ole Isacson Chief Scientific Officer
  • Mikael Dolsten President-Worldwide Research & Development
  • More

Research & Ratings Pfizer Inc.PFE

Per-Share Earnings, Actuals and Estimates

  • Quarterly
  • Annual
PFE will report FY 2016 earnings on 01/31/2017 PFE will report Q4 earnings on 01/31/2017
Actual Analyst Range Consensus
0.80 0.70 0.60 0.50
Actual 0.53
0.52
Actual 0.67
0.55
Actual 0.64
0.62
Actual 0.61
0.62
0.51
0.65
Q42015 Q12016 Q2 Q3 Q4 Q12017
4 3 2 1 0
Actual 1.11
2.19
2.42
2.61
2.84
FY 2015 FY 2016 FY 2017 FY 2018
Q4 2016 Estimate Trends
Current: $0.51
1 month ago: $0.54
3 months ago: $0.54
Q1 2017 Estimate Trends
Current: $0.65
1 month ago: $0.68
3 months ago: $0.65
FY 2016 Estimate Trends
Current: $2.42
1 month ago: $2.46
3 months ago: $2.46
FY 2017 Estimate Trends
Current: $2.61
1 month ago: $2.67
3 months ago: $2.64
  • More

Financials Pfizer Inc.PFE

  • Quarterly
  • Annual

Net Income

0 800M 1.6B 2.4B 3.2B
0 -800M
Sep 2015 Dec 2015 Mar 2016 Jun 2016 Sep 2016
0 3B 6B 9B 12B
'11 '12 '13 '14 '15
Sep 2016 5-quarter trend
Net Income Growth -37.77%
Sales or Revenue 13.05 B
Sales or Revenue Growth +7.93%
EBITDA -
2015 5-year trend
Net Income Growth -23.53%
Sales or Revenue 48.85 B
Sales or Revenue Growth -1.52%
EBITDA +18.45 B
  • More
  • Overview

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement
  • Wall Street Journal
  • 日本 (Japan)
    • U.S.
    • Asia
    • Europe
    • India
    • América Latina
    • Brasil
    • 中国 (China)
    • 日本 (Japan)
  • Subscribe NowSign In

  • Newsletter
  • WSJ Membership Benefits
  • Download WSJ Apps
  • Customer Center
  • Legal Policies
  • Subscribe
  • Sign In
  • TOP«
  • Customer Service

  • Customer Center
  • Contact Us
  • About Houjin Subscribing
  • 学生割引購読
  • About Us
  • Ads

  • About Ads
  • Tools & Features

  • iPhone App
  • iPad App
  • Android App
  • Newsletter
  • About Japanese Blog Parts
  • More

  • Events
  • Jobs at WSJ
    • Facebook
    • Twitter
    • Line
    • Google+
    • YouTube
    • Podcasts
    • Snapchat
    • GooglePlay
    • AppStore
    • Windows10
  • Dow Jones Products
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Private Markets
  • realtor.com
  • Risk & Compliance
  • WSJ Conference
  • WSJ Pro Central Banking
  • WSJ Video
  • WSJ Wine
  • BallBall
  • Privacy Policy
  • Cookie Policy
  • Tokusyo
  • Data Policy
  • Subscriber Agreement & Terms of Use
  • Copyright ©2016 Dow Jones & Company, Inc. All Rights Reserved.